Table 9.
Discounted ICER ($) of different Interferons-Beta in comparison to placebo therapy in MS patients according to different utility measurement methods
| Therapy | Literature-based | VAS | EQ-5D | HUI 3 |
|---|---|---|---|---|
|
Interferon beta-1a |
18873 |
20370 |
18050 |
20104 |
|
(Avonex) | ||||
|
Interferon beta-1a |
13482 |
13885 |
12347 |
13092 |
|
(Rebif) | ||||
|
Interferon beta-1b |
15142 |
16452 |
14808 |
15663 |
|
(Betaferon) | ||||
|
Interferon beta-1a |
4026 |
4345 |
3850 |
4288 |
|
(Intramuscular) | ||||
|
(CBPs) | ||||
|
Interferon beta-1a |
9553 |
9838 |
8749 |
9276 |
|
(Subcutaneous) | ||||
|
(CBPs) | ||||
|
Interferon beta-1b |
11903 | 12933 | 11641 | 12312 |
| (CBPs & BS) |
$ US dollars, ICER incremental cost effectiveness ratio, VAS visual analogue scale, EQ-5D EuroQol, HUI 3 Health Utilities Index 3, CBPs Copied biopharmaceuticals including IM IFNβ-1a (Cinnovex, Actovex), SC IFNβ-1a (Recigen, Actorif ) and SC IFNβ-1b (Ziferon, Actoferon), BS biosimilar including SC IFNβ-1b (Extavia).